Cambridge Healthtech Institute’s 9th Annual

Engineering Antibodies & Beyond

Designing the Next Best-in-Class Biologics

6 November 2024


The pursuit of more precise, safe, yet potent therapies drives the evolution of drug design far beyond traditional boundaries. The Engineering Antibodies & Beyond conference offers a deep dive into cutting-edge technologies and novel strategies that are reshaping the future of medicine. From harnessing radiotherapeutics to protein degradation, we will explore solutions for targeted delivery, conditional drug activation, and investigate the potential of bioprinting, with the ultimate goal of ensuring target specificity, effective delivery, and patient safety.

Coverage will include, but is not limited to:

  • Engineering Radiotherapeutics
    • Targeted delivery of radioisotope while minimising off-target toxicity
    • Optimising the dose of radiation to maximise therapeutic effect
    • Choosing the vector class for your radiotherapeutics—cyclic peptides, mini proteins, antibodies

  • Masking to Mitigate Systemic Toxicity—Conditional Activation, Switches, Logic-Gating, Armoring
    • Ensuring masking strategy doesn’t interfere with the drug’s activity at target site
    • Specificity of triggers to precisely activate only in the tumour microenvironment
    • Stability and immunogenicity concerns

  • Protein Degraders and Targeted Therapies
    • Designing antibody-based degraders for specific disease targets
    • Specificity and off-target effects
    • Developing strategies to deliver protein degraders (e.g., PROTACs, LYTAcs, ATTECs) into cells effectively
    • Conjugating degraders with peptides or using nanoparticle delivery systems

  • Exosomes as a New Modality
  • Bioprinting and Tissue Engineering
    • Using antibodies to guide bioprinting of complex tissues and organs
    • Printing functional tissues and organs for cell manipulation and tissue regeneration
    • Developing personalised medicine approaches using bioprinted tissues

The deadline for priority consideration is 29 March 2024.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation:

For more details on the conference, please contact:

Mimi Langley
Senior Conference Director
Cambridge Healthtech Institute
Phone: (+1) 781-972-5439
Email: mlangley@healthtech.com

For sponsorship information, please contact:

Companies A-K
Jason Gerardi
Sr. Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5452
Email: jgerardi@healthtech.com

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-1340
Email: ashleyparsons@healthtech.com